BioSpace News Archive

The College of American Pathologists, in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer who are being considered for immunooncology therapy.

AzurRx BioPharma, Inc. announced that the Company will host a conference call and live audio webcast today, Wednesday, March 31, 2021, at 4:30 p.m. ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder value

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, reported financial results and a business update for the three months and full year ended December 31, 2020.

Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse, part of the National Institutes of Health, to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose.

Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021

Universe Pharmaceuticals INC, a pharmaceutical producer and distributor in China, announced the underwriter of its previously announced initial public offering of ordinary shares has exercised in full its option to purchase an additional 750,000 ordinary shares at the public offering price of $5.00 per share to cover overallotments, resulting in additional gross proceeds of $3.75 million.

Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the Zydus Group, signed a Development and Asset Purchase Agreement for CUTX-101 for the treatment of Menkes disease

Sonoma Pharmaceuticals, Inc. announced that it has entered into an agreement with EMC Pharma, LLC for the exclusive right to manage, market and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for an initial term of five years, subject to extension.